๐Ÿ”† ๐Ÿ“– โž• ๐Ÿ‘ค

Statutory Instruments

2016 No. 1124

Dangerous Drugs

The Misuse of Drugs (Designation) (Amendment) (England, Wales and Scotland) Order 2016

Made

21st November 2016

Laid before Parliament

23rd November 2016

Coming into force

14th December 2016

The Secretary of State makes the following Order in exercise of the powers conferred by sections 7(4) and 7(5) of the Misuse of Drugs Act 1971( 1 ).

In accordance with section 7(7) of that Act the Secretary of State has consulted with the Advisory Council on the Misuse of Drugs.

Citation, commencement and extent

1. โ€”(1) This Order may be cited as the Misuse of Drugs (Designation) (Amendment) (England, Wales and Scotland) Order 2016 and comes into force on 14th December 2016.

(2) This Order extends to England and Wales and Scotland.

Amendment to the Misuse of Drugs (Designation) (England, Wales and Scotland) Order 2015

2. โ€”(1)The Misuse of Drugs (Designation) (England, Wales and Scotland) Order 2015( 2 ) is amended as follows.

(2) After paragraph 1(s) of Part 1 of Schedule 1 (which specifies controlled drugs to which section 7(4) of the Misuse of Drugs Act 1971 applies) insertโ€”

โ€œ (sa) any compound (not being clonitazene, etonitazene, acemetacin, atorvastatin, bazedoxifene, indometacin, losartan, olmesartan, proglumetacin, telmisartan, viminol, zafirlukast or a compound for the time being specified in sub-paragraphs (h) to (s) above) structurally related to 1-pentyl-3-(1-naphthoyl)indole (JWH-018), in that the four sub-structures, that is to say the indole ring, the pentyl substituent, the methanone linking group and the naphthyl ring, are linked together in a similar manner, whether or not any of the sub-structures have been modified, and whether or not substituted in any of the linked sub-structures with one or more univalent substituents and, where any of the sub-structures have been modified, the modifications of the sub-structures are limited to any of the following, that is to sayโ€”

(i) replacement of the indole ring with indane, indene, indazole, pyrrole, pyrazole, imidazole, benzimidazole, pyrrolo[2,3-b]pyridine, pyrrolo[3,2-c]pyridine or pyrazolo[3,4โ€‘b]pyridine;

(ii) replacement of the pentyl substituent with alkyl, alkenyl, benzyl, cycloalkylmethyl, cycloalkylethyl, ( N -methylpiperidin-2-yl)methyl, 2-(4-morpholinyl)ethyl or (tetrahydropyran-4-yl)methyl;

(iii) replacement of the methanone linking group with an ethanone, carboxamide, carboxylate, methylene bridge or methine group;

(iv) replacement of the 1-naphthyl ring with 2-naphthyl, phenyl, benzyl, adamantyl, cycloalkyl, cycloalkylmethyl, cycloalkylethyl, bicyclo[2.2.1]heptanyl, 1,2,3,4-tetrahydronaphthyl, quinolinyl, isoquinolinyl, 1-amino-1-oxopropan-2-yl, 1โ€‘hydroxy-1-oxopropan-2-yl, piperidinyl, morpholinyl, pyrrolidinyl, tetrahydropyranyl or piperazinyl; โ€ .

Sarah Newton

Parliamentary Under Secretary of State

Home Office

21st November 2016

Status: This is the original version (as it was originally made). This item of legislation is currently only available in its original format.
The Misuse of Drugs (Designation) (Amendment) (England, Wales and Scotland) Order 2016 (2016/1124)

Displaying information

Status of this instrument

footnotecommentarytransitional and savingsin force statusrelated provisionsgeo extentinsert/omitsource countin force adj
Defined TermSection/ArticleIDScope of Application

Status of changes to instrument text

The list includes made instruments, both those in force and those yet to come into force. Typically, instruments that are not yet in force (hence their changes are not incorporated into the text above) are indicated by description 'not yet' in the changes made column.